These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17306444)

  • 1. Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
    Bracarda S
    Eur Urol; 2007 Dec; 52(6):1698-9. PubMed ID: 17306444
    [No Abstract]   [Full Text] [Related]  

  • 2. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
    Fosså SD; Jacobsen AB; Ginman C; Jacobsen IN; Overn S; Iversen JR; Urnes T; Dahl AA; Veenstra M; Sandstad B
    Eur Urol; 2007 Dec; 52(6):1691-8. PubMed ID: 17306441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.
    Fosså SD
    Front Radiat Ther Oncol; 2008; 41():108-116. PubMed ID: 18544992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
    Arlen PM; Gulley JL
    Future Oncol; 2005 Feb; 1(1):19-22. PubMed ID: 16555972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
    Ito H; Inamura S; Taga M; Tsuchiyama K; Kusukawa N; Oyama N; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1245-7. PubMed ID: 24047790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
    Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonging survival in prostate cancer: chemotherapy will have an important role.
    Parker C; Emberton M
    BJU Int; 2005 Jul; 96(1):2-3. PubMed ID: 15963108
    [No Abstract]   [Full Text] [Related]  

  • 8. [A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
    Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):841-4. PubMed ID: 16770110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Taneja SS
    J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209521
    [No Abstract]   [Full Text] [Related]  

  • 10. Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
    Ide H; Kikuchi E; Kono H; Nagata H; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
    Jpn J Clin Oncol; 2010 Jan; 40(1):79-84. PubMed ID: 19837689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
    Perry CJ; Sundar S
    Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
    [No Abstract]   [Full Text] [Related]  

  • 13. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
    J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
    Rulach RJ; McKay S; Neilson S; White L; Wallace J; Carruthers R; Lamb C; Cascales A; Marashi H; Glen H; Venugopal B; Sadoyze A; Sidek N; Russell JM; Alhasso A; Dodds D; Laskey J; Jones RJ; MacLeod N
    BJU Int; 2018 Feb; 121(2):268-274. PubMed ID: 28940952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 16. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
    Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
    Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Scleroderma-like skin sclerosis induced by docetaxel chemotherapy for hormone refractory prostate cancer: a case report].
    Maehana T; Mizuno T; Muto M; Nishiyama N; Yanase M
    Nihon Hinyokika Gakkai Zasshi; 2010 Sep; 101(6):726-9. PubMed ID: 20954379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.
    Di Lorenzo G
    Eur Urol; 2008 Feb; 53(2):332. PubMed ID: 17445974
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.
    Bracarda S
    Eur Urol; 2008 Feb; 53(2):331. PubMed ID: 17445971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.